We Help Companies Find New Sales Opportunities
Chemicals & Pharmaceuticals - 2009
AstraZeneca is to acquire Novexel, the French infection research company, for up to £266m, and will collaborate with US-based Forest Laboratories in the development of two antibiotics.
Cobra Biomanufacturing, the Keele-based vaccine manufacturer with 80 staff, has recommended a takeover bid from Recipharm of Sweden that values the company at about £1m.
Lab21 has acquired Selah Technologies, the US nanotechnology company, for undisclosed terms.
Avecia Biologics, the Billingham-based biotechnology company with 500 staff, is to be acquired by Merck for undisclosed terms.
GlaxoSmithKline has confirmed that its Barnard Castle site is one of three potential locations for a new £300m biopharmaceuticals factory, which could create hundreds of jobs.
Genetix Group, the cell imaging company with sites in Hampshire and Gateshead, is to be acquired by Danaher Corp of the US for £63m.
TrichoTech is planning to expand the workforce at its Cardiff-based drug and alcohol testing business from 50 to 60 early next year.
Silence Therapeutics is to acquire Intradigm, the US biotechnology company specialising in experimental medicines based on RNA interference, for £16m.
McBride has acquired Homepride, the Milton Keynes-based supplier of cleaning products, for undisclosed terms.
Alberto Culver is to acquire the Simple skin care brand in the UK from Duke Street for £240m.
Pentagon Chemicals has secured a £2m investment from Maven Capital Partners to fund the expansion of its chemicals business, which has 160 staff in Cheshire and Cumbria.
Circassia of Oxford has raised £15m to fund the development of allergy treatments.
Scottish Enterprise has announced government funding of £24m for the development of a "bioincubator" in Edinburgh's BioQuarter, in order to create up to 200 jobs in the biotechnology sector over the next five years.
Marken is to sell a majority stake in its London-based pharmaceuticals support services business to private equity firm Apax Partners in a £975m deal.
Reckitt Benckiser is to relocate 90 office-based jobs from Hull to Slough over the next few months.
Exwold is planning to set up a new 8,000 sq ft crop protection chemicals plant on the Queens Meadow Business Park in Hartlepool, and also hopes to open a factory in Brazil.
Lab21 has acquired the business and assets of Delphic Diagnostics, the laboratory services firm with sites in Liverpool and Kent, out of administration for undisclosed terms.
Ineos Chlor Vinyls has announced plans for a multi-million pound investment in the expansion of its chloromethane production plant in Runcorn over the next five years.
Intercytex has closed its operation in Cambridge, as part of a restructuring of its stem cell business which includes the sale of its Axordia subsidiary to Pfizer for £0.5m.
Ashfield In2Focus is to invest £7m in the expansion of the Ashby-based headquarters of its pharmaceutical training business, with the creation of up to 50 jobs, including the relocation of its Universal Procon division from Slough.
Epistem is to raise £2.9m in a share placing to fund the expansion of its Manchester-based biotechnology business.
Plethora Solutions is to raise £1.6m in a share placing to fund the creation of a new subsidiary to supply therapeutic products to urology clinics.
Orthomimetics, the Cambridge-based regenerative medicine firm with 11 staff, has been acquired by TiGenix of Belgium for £14m.
Bristol-Myers Squibb is investing a further £3.5m in the expansion of its pharmaceuticals research and development centre in Wirral, in order to create new laboratories and secure 100 jobs.
Conformetrix, the Manchester-based drug development company, has secured an undisclosed equity investment from the Aquarius Origin Fund and aims to expand its workforce from five to 15 by 2011.
ScriptSwitch, the Coventry-based provider of drug comparison software to doctors with 45 staff, is to be acquired by UnitedHealth of the US.
Smith & Nephew is to acquire the assets of Nucryst Pharmaceuticals, the US manufacturer of antimicrobial dressings, for £13m.
Quay Pharma is to relocate from Bromborough to a new £2.7m pharmaceuticals research and development centre at Deeside Industrial Park in Flintshire in January, with the creation of 54 jobs.
One North East has announced that INEOS Bio is conducting a £3.5m feasibility study into the development of a waste-fuelled bioethanol plant at Seal Sands in the Tees Valley.
E-Therapeutics has raised £2.5m in a share placing to fund the expansion of its drug discovery business.
Phoenix Chemicals has secured a Scottish Government grant to reopen the former Shasun pharmaceutical chemicals plant in Annan, as part of a £4m investment that will create 58 jobs over the next three years.
Brunner Mond is planning to build a sustainable energy plant fuelled by biomass and pre-treated waste at its chemicals site in Lostock, Cheshire, in partnership with Eon.
SCM Pharma is looking to expand the workforce at its Northumberland-based pharmaceuticals production business from 43 to almost 70 next year.
Avacta Group is to raise £2m in a share placing to fund the expansion of its York-based pharmaceuticals and diagnostic tests business.
Ranbaxy Laboratories is to relocate the London headquarters of its pharmaceuticals business from Ealing to a 5,000 sq ft office at Chiswick Park.
Parkwood has acquired full ownership of its Exeter-based Verdia horticultural compost manufacturing joint venture from TEG Group.
GlaxoSmithKline is to provide land and facilities worth £11m to a joint venture with the government and Wellcome Trust to build a new £37m bioscience campus in Stevenage, which could create up to 1,500 jobs.
Sinclair Pharma has acquired the Flammazine and Flammacerium dermatology products from Solvay Pharmaceuticals for £16m.
New Horizons Global is planning to expand the 18-strong workforce at its biotechnology operation in Knowsley to 60 over the next year, following a £1.4m investment in the production of omega-3 oil.
Third Coast Chemicals of the US is to seek government support to invest £50m in the overhaul of a former ICI chemicals plant at Wilton on Teesside, in order to produce diethylene and triethylene glycol.
Advanced Medical Solutions has acquired the remaining 51% of Corpura, the Dutch supplier of wound dressings with 15 staff, for £2m.
Quintiles Transnational Corp is creating a further 150 jobs at its new 115,000 sq ft biopharmaceutical services site in Livingston.
Thornton & Ross has acquired Zeroderma, the Leicestershire-based supplier of dermatological creams, for undisclosed terms.
Unilever is to acquire the personal care division of Sara Lee for £1.2bn, including a bath products factory in Slough that employs 300.
Consort Medical is to acquire The Medical House, the Sheffield-based drug injection firm, for about £16m.
Mawdsley Brooks has expanded its Salford-based pharmaceuticals wholesaling business with the acquisition of Midlands-based National Generics and Scotland-based Eclipse Generics.
Almac Laboratories has secured planning permission for the multi-million pound expansion of its pharmaceutical operations in Portadown, which will lead to the creation of up to 500 jobs.
DxS, the Manchester-based manufacturer of genetic testing kits with 90 staff, has been acquired by Qiagen of Germany for up to £79m, and will soon relocate to a larger site at Manchester Science Park.
Provexis is in discussions to raise £5m from investors to fund the expansion of its biotechnology operations in Windsor and Liverpool.
Cancer Research UK is providing £8m for the development of a drug discovery centre in Manchester, while £8m will go to the Beatson Institute in Glasgow and £5m to Oxford and Southampton universities.
The University of Liverpool has submitted plans to build a £90m cancer research centre in Crown Street by 2011.
Excalibur has acquired International Biosciences Managers, the biotechnology advisory and fund management firm, for undisclosed terms.
Renovo is planning to shed up to one third of the 180 jobs at its Manchester-based biotechnology business, in order to focus on the development of anti-scarring drugs.
Randox Laboratories is to create a further 34 jobs at its biotechnology business in County Antrim.
Phoenix Chemicals has acquired the former Shasun Pharma Solutions pharmaceuticals plant near Annan in Dumfries & Galloway for undisclosed terms, which could lead to the creation of about 70 jobs.
Jotun Paints (Europe) is planning a multi-million pound expansion of its paints factory in Flixborough, with the creation of an unspecified number of jobs.
Myconostica has raised a further £1.7m of venture capital to fund the expansion of its Manchester-based medical diagnostics business.
Dechra is to invest £1m in the expansion of its animal medicines site in Talke, North Staffordshire, including a new warehouse on the Jamage Industrial Estate.
Lab901 has raised a further £2.4m from investors to fund the expansion of its Edinburgh-based laboratory testing systems business.
Summit Corporation has sold its Dextra Laboratories chemistry services division to New Zealand Pharmaceuticals for £1m, in order to focus on its Oxfordshire-based drug discovery business.
The University of Liverpool has unveiled plans to build a new £25m science laboratory on Chatham Street North by September 2011.
Alliance Pharma is to acquire the worldwide rights to the Buccastem and Timodine prescription brands from Reckitt Benckiser for £7.5m.
Nova Laboratories is to set up a new £2m factory to manufacture bone cement for hip replacements near its existing site in Leicestershire by December, with the creation of up to 60 jobs.
North Lincolnshire Council is supporting John Carson Innovations in the development of a new Limelite fertiliser pellets factory in Bonby, with the creation of 24 jobs.
York Pharma, the Milton Keynes-based pharmaceuticals company, has been bought out of administration by RH Acquisitions.
Celsis International, the laboratory services company, is to be acquired by Nastor Investments for £54m.
AstraZeneca is planning to relocate its London headquarters from Mayfair to a 60,000 sq ft office in Paddington next year.
The Institute for Animal Health has secured a £100m government grant to build new laboratories at its site in Pirbright, Surrey.
Aesica is to invest £5m in the expansion of its pharmaceuticals research centre in Cramlington over the next three years, and is now looking to recruit up to 30 scientists.
Union Colours has bought the Stockport-based technical centre of European Colour Pigments out of administration for undisclosed terms, securing 15 jobs.
Reckitt Benckiser is to invest £13m in new health care manufacturing facilities at its site in Hull, with the creation of 60 jobs.
The Department for Business Innovation & Skills is to invest £12m in a new industrial biotechnology demonstrator facility at Wilton on Teesside by next year, with the creation of up to 40 jobs.
Swansea University has secured funding of £30m to expand its medical research institute by 2011, with the creation of up to 650 jobs.
Animalcare is looking to spend up to £10m on acquisitions to expand its North Yorkshire-based pet drugs business.
Everbuild Building Products has acquired Feb, the Manchester-based manufacturer of building chemicals, and production will transfer to Everbuild's factory in Leeds.
ICON has acquired Veeda Laboratories, the Oxford-based supplier of biomarker laboratory services, from Veeda Clinical Research.
The Scottish Government is to provide funding of £3m to enable life sciences companies to employ 100 apprentices, and the initiative will be implemented by Skills Development Scotland.
Eisai has opened its new £100m pharmaceuticals manufacturing and research facility in Hatfield, which will create 250 research jobs.
Quotient Bioresearch is to acquire the Amersham Radiolabeling Services laboratories in Cardiff, in a £15m deal that will secure 75 jobs and create 40 new jobs.
Chroma Therapeutics of Oxfordshire has agreed a deal worth up to £750m with GlaxoSmithKline to develop new drugs for inflammatory disorders.
Brotherton Speciality Products is to invest £4m in the expansion of its sulphites production facility in Wakefield.
ICON and the Central Manchester University Hospitals Foundation Trust are to set up a pharmaceuticals research facility at the Manchester Royal Infirmary by 2012.
Allergy Therapeutics is to raise up to £22m in a share placing, in order to invest in European sales and marketing for its pharmaceuticals business.
Concateno, the drug and alcohol testing company with sites in Abingdon, London, Cardiff and Spain, is to be acquired by Inverness Medical Innovations in a £147m deal.
Oxford Biosensors has gone into administration through Tenon Recovery, with the loss of 31 jobs, having failed to secure funding for the development of its cholesterol monitor.
Proximagen Neuroscience has raised £50m in a share placing, in order to fund the expansion of its London-based drug development business.
Reckitt Benckiser is to relocate about 100 sales, marketing and finance jobs from Swindon to its head office in Slough.
MacDermid is creating up to 100 jobs at its new £15m chemicals research and development laboratory in Small Heath, Birmingham.
Lab21 has acquired Plasmatec Laboratory Products, the Dorset-based diagnostic tests manufacturer, from Axis-Shield for undisclosed terms.
University of Central Lancashire has unveiled plans to invest £12m in the expansion of its forensic and pharmaceutical sciences facility in Preston.
AstraZeneca has awarded a £45m contract to Mott MacDonald to build a four-storey research centre at its Alderley Park site in Cheshire.
The Specials Laboratory is planning to expand the 135-strong workforce at its pharmaceuticals business in Prudhoe, Northumberland, to 150 over the next year.
Summit Corporation has sold its Oxfordshire-based Zebrafish services division to Evotec for £0.5m, in order to focus on its drug discovery operation.
Semiramis Genetics is to set up a new headquarters for its life sciences business at the Manchester Science Park in June.
Genetix Group has acquired SlidePath, the Irish cell imaging firm with 25 staff, for up to £3.3m.
Morgan Ashurst has won a £12m contract from the National Institute for Biological Standards & Control to build a stem cell bank and influenza resource centre at South Mimms in Hertfordshire by December, and the site will employ 35 scientists.
GlaxoSmithKline is to acquire Stiefel Laboratories, the US dermatology company with 3,500 staff, for up to £2.4bn.
Druckfarben has bought certain assets of Shackell Edwards & Co, the Stockport-based ink manufacturer, out of administration.
Sygnature Chemical Services is planning to double the size of its pharmaceuticals research business at the BioCity centre in Nottingham over the next two years, and 15 chemists will be added to the 35-strong workforce.
Genzyme is to expand the 100-strong workforce at its Oxford-based biotechnology business with ten new jobs, having agreed a strategic partnership with Bayer.
Diurnal is to relocate its drug development business from Sheffield to Cardiff, having received a £0.25m investment from Finance Wales, Fusion IP and the Viking Fund.
Weilburger Coatings of Runcorn has acquired Trimite, the industrial coatings manufacturer with sites in Uxbridge, Bristol, Belfast and Glasgow.
BioVex, the biotechnology company with offices in Oxford and the US, has raised a further £30m of capital to expand its business.
One NorthEast has unveiled plans for a £1.8m investment in the health care and life sciences sector, with the creation of 58 jobs at NHS Innovations North.
Oxford Gene Technology has acquired Sense Proteomic, the Maidenhead-based biotechnology firm with eight staff, taking its total workforce to more than 50.
Pivotal Laboratories, the York-based clinical trials and pharmaceutical services firm with 38 staff, has been acquired by ACM of the US for undisclosed terms.
Dales Engineering Services has acquired LJF Powder Coatings, the Aberdeen-based supplier of surface coatings with eight staff, for more than £1m.
AstraZeneca has appointed CB Richard Ellis to find a suitable 60,000 sq ft site for a new headquarters in London, and is expected to relocate from Stanhope Gate by 2010.
One NorthEast has assisted Nanjing Chuanbo Biotech of China in setting up a European headquarters for its drug development business at the International Business Centre in Gateshead, and a number of new jobs will be created.
The Biotechnology & Biological Sciences Research Council (BBSRC) is expected to announce plans for the development of a £13m Genome Analysis Centre at the Norwich Research Park, which could create up to 750 science jobs.
Merck is to acquire Schering-Plough for $41m, creating a global pharmaceuticals group with a combined UK workforce of almost 3,000 at sites including Hoddesdon, Cramlington, Welwyn Garden City, Newhouse and Milton Keynes.
Lab21 has acquired Biotec Laboratories, the Ipswich-based clinical diagnostics firm, for undisclosed terms.
Penn Pharma is to invest £12m in the expansion of its biosciences operation in Tredegar, with the creation of 133 jobs.
Clariant has confirmed plans to close its speciality chemicals plant in Horsforth, West Yorkshire, with the loss of 160 jobs, and is seeking a suitable site nearby to relocate the remaining 80 staff.
DxS is planning to expand the 60-strong workforce at its Manchester-based biotechnology business with 20 additional scientists and support staff this year.
Schering-Plough is to invest about £20m in the expansion of its drug discovery research centre in Newhouse, Lanarkshire.
Avacta Group has acquired YorkTest Veterinary Services, the York-based veterinary laboratory services firm, for up to £0.8m.
Almac Group is to increase the 1,559-strong workforce at its pharmaceuticals research and development business in Northern Ireland with the recruitment of 54 additional staff over the next few months.
Quantum Specials, the County Durham-based manufacturer of bespoke drugs with more than 100 staff, has undergone a £32m management buy-out backed by Lloyds TSB Development Capital.
Jeyes is to create 50 jobs at its cleaning products factory in Thetford over the next three months, following the transfer of production from its Powder & Liquid Products site in Consett.
PZ Cussons is to close its fragrance chemicals plant in Ellesmere Port over the next few months, in order to relocate production and the 25 jobs to its new £26m site in Manchester.
Brunner Mond is to invest £18m at its Cheshire-based soda ash manufacturing operations, in order to cut energy costs and improve environmental performance.
Unilever has acquired TIGI, the owner of Toni & Guy hair product ranges such as S-Factor, Bed Head and Catwalk, for £295m.
GlaxoSmithKline is to acquire a portfolio of more than 50 medicines in Africa, Asia Pacific, Latin America and the Middle East from UCB of Belgium for £486m.
Croda International is to relocate its chemicals distribution business from Doncaster to an 83,500 sq ft unit being built at Capitol Park in Thorne.
Avacta Group has acquired Theragenetics, the medical diagnostics company with offices in London and the US, for up to £2m.
Fine Organics, the Billingham-based intermediary chemicals manufacturer with 218 staff, has undergone a management buy-out from Evonik Degussa of Germany for undisclosed terms.
Avacta Group is to acquire Curidium Medica, the London-based biotechnology and diagnostics firm, for about £6.2m.
Yule Catto is to sell Oxford Chemicals, the Hartlepool-based manufacturer of aroma chemicals with 70 staff, to Frutarom for £8.2m.